Antares Pharma Appoints Jonathan S. Jaffe MD Vice President of Clinical Development

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Jonathan S. Jaffe MD to the position of Vice President of Clinical Development. Jonathan’s background includes a 12 year post-graduate career in academic medicine and more than 15 years of experience in global drug development in the pharmaceutical industry.

“We are very pleased to add another experienced pharmaceutical executive to the Antares development team,” said Kaushik J. Dave R.Ph., Ph.D., and Executive Vice President Product Development. “Jonathan’s previous broad experience as a pharmaceutical clinician will be extremely valuable as we continue to execute on the development of our pipeline products.”

Dr. Jaffe received a Bachelor of Arts degree in Biology from Lehigh University and an MD from the Jefferson Medical College of Thomas Jefferson University in Philadelphia. He completed a residency in Internal Medicine at Lenox Hill Hospital, followed by clinical and laboratory fellowships at the Laboratory of Clinical Investigation, NIAID, NIH, while in the Research Officers Group of the Public Health Service. Following fellowship, Dr Jaffe served on the full-time academic faculty of Hahnemann (now Drexel) University Medical School where he conducted research, taught in the clinics and provided medical care. In 1996 Dr Jaffe began his pharmaceutical career, conducting clinical studies in a variety of transplant indications for Wyeth-Ayerst Research, led global clinical development programs, conducting all phases of research, for respiratory, transplant and autoimmune indications at Schering Plough Research Institute, Novartis, and Forest Research Institute. Immediately prior to joining Antares, Dr Jaffe served on a consulting basis for Pharmanet-i3 as a clinical program leader in inflammatory bowel disease in Pfizer’s Bio-therapeutics Unit. His work on clinical development programs has resulted or contributed to multiple regulatory approvals of compounds both in the US and abroad including Rapamune, Remicade, Xolair, Zortress, and Daliresp.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors distributed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is Gelnique 3%™ for the treatment of OAB (overactive bladder) marketed by Watson Pharmaceuticals, Inc. in the U.S. Antares’ portfolio includes Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the development and manufacturing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Group are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.